Therefore, well-established immunohistochemical (IHC) staining techniques for the detection of p53 and MMR proteins (MLH1, PMS2, MSH2, MSH6) are now recommended as standard practice for all endometrial cancer pathology specimens, regardless of histological type, together with sequencing of the exonuclease domain of POLE if available.17 This evidence concerns the gene MLH1 and endometrial cancer.